Kissei Pharmaceutical has become the cancer immunotherapy developer's first corporate investor, in a series D round bringing its overall funding to $93.5m.
US-based cancer immunotherapy developer CG Oncology has closed a $47m series D round led by drug producer Kissei Pharmaceutical that included Ori Healthcare Fund, Camford Capital and Perseverance Capital Management.
Founded in 2010 as Cold Genesis, CG Oncology is working on oncolytic immunotherapies, a type of treatment that uses viruses to infect and destroy cancer cells. Its drug candidates are genetically engineered to launch multi-pronged attacks on advanced forms of cancer.
The series D cash will progress late-clinical research on…
